LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Nuclear Hormone Expression Predicts Cancer Aggressiveness

By LabMedica International staff writers
Posted on 15 Apr 2019
Print article
Image: Pancreatic cancer cells (blue) growing as a sphere encased in membranes (red) (Photo courtesy of the U.S. National Cancer Institute).
Image: Pancreatic cancer cells (blue) growing as a sphere encased in membranes (red) (Photo courtesy of the U.S. National Cancer Institute).
A large-scale retrospective analysis in patients revealed that expression of the nuclear hormone receptor "retinoic-acid-receptor-related orphan receptor gamma" (RORgamma) could predict pancreatic cancer aggressiveness, since it correlated positively with advanced disease and metastasis.

Drug resistance and relapse remain key challenges in pancreatic cancer, with current multidrug chemotherapy regimens failing to eradicate all cancer cells. The remaining drug-resistant cancer stem cells can drive tumor regrowth and metastasis.

Investigators at the University of California, San Diego (USA) used RNA sequencing (RNA-seq), chromatin immunoprecipitation (ChIP)-seq, and genome-wide CRISPR analysis to map the molecular dependencies of pancreatic cancer stem cells.

This integrated genomic approach revealed an unexpected utilization of immuno-regulatory signals by pancreatic cancer epithelial cells. In particular, RORgamma, known to drive inflammation and T-cell differentiation, was upregulated during pancreatic cancer progression. In contrast, genetic or pharmacologic inhibition of RORgamma led to a striking defect in pancreatic cancer growth and a marked improvement in survival. Furthermore, a large-scale retrospective analysis in patients revealed that RORgamma expression could predict pancreatic cancer aggressiveness, as it positively correlated with advanced disease and metastasis.

"These studies revealed an unexpected role for immuno-regulatory genes in the maintenance of the most aggressive, drug-resistant cells in pancreatic cancer," said senior author Dr. Tannishtha Reya, professor of pharmacology and medicine at the University of California, San Diego. "Our work shows that immune system signals are hijacked by pancreatic cancer, and suggests that therapies currently being tested for autoimmune indications should be considered for testing in pancreatic cancer.

"Using genome scale approaches to map stem cell dependencies in pancreatic cancer will be invaluable for understanding the basis of therapy resistance and recurrence and for discovering new vulnerabilities in pancreatic cancer. Beyond providing new scientific insight, this work can help identify pathways for which clinical grade inhibitors may already exist and can thus be rapidly tested in pancreatic cancer," said Dr. Reya.

The RORgamma paper was published in the April 4, 2019, online edition of the journal Cell.

Related Links:
University of California, San Diego

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more